Older patients with acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (aMDS) must decide between receiving intensive induction chemotherapy (IC) or nonintensive chemotherapy/best supportive care (NIC). Little information exists about what factors influence treatment decisions and what quality of life (QOL) is associated with treatment choices. We prospectively examined 43 patients 60 years or older who were interviewed at diagnosis and periodically over 1 year. IC choice was associated with younger age (66 vs 76 years, P ¼ 0.01) and AML diagnosis, but not with performance status, comorbidities, or QOL. In total, 63% of all patients reported not being offered other treatment options despite physician documentation of alternatives. Patient and physician estimates of cure differed significantly: 74% of patients estimated their chance of cure to be 50% or greater, yet for 89% of patients physician estimates of cure were 10% or less. IC patients experienced decreased QOL at 2 weeks, but rebounded to baseline and to NIC levels by 6 weeks. Initial QOL is not associated with treatment choice in older AML and aMDS patients. Regardless of treatment choice, patients report not being offered treatment options and overestimate their chances of cure. In IC patients, QOL decreases during hospitalization but rebounds after discharge.
Introduction
Acute myeloid leukemia (AML) affects 2.7 per 100 000 people in the United States each year, and from 0.3 to 5.3 per 100 000 in populations around the world. 1, 2 If untreated, death results from bleeding or infectious complications, with a median survival of approximately 2 months. 3, 4 Standard remission induction therapy consisting of an anthracycline and cytosine arabinoside [5] [6] [7] [8] [9] [10] can effect complete remission (CR) rates of 65-73% in patients under the age of 60 years, and long-term disease-free survival (DFS) rates of 30%, although treatment-related mortality approaches 5-10%. 7, 8, [11] [12] [13] However, AML is a disease of older adults, with a median age at diagnosis of approximately 67 years in the United States.
14 It affects 14.1 per 100 000 US citizens over the age of 65 years. 1 Aggressive induction therapy in older patients results in CR rates of 40-55%, with up to 25% treatment related mortality and only 5-15% long-term DFS. [15] [16] [17] [18] The median survival of older adults receiving induction therapy is only 10 months. This is likely due to concomitant comorbidities, different disease biology, and differential chemotherapy metabolism compared to younger patients. 7, 19, 20 For example, older patients have a higher incidence of unfavorable chromosomal abnormalities, a lower incidence of favorable ones, and are more likely to have secondary AML. 10, [21] [22] [23] [24] [25] Patients with high risk or advanced myelodysplastic syndrome (aMDS), also a condition affecting older adults, have a disease that runs an accelerated course with a similar prognosis to patients with AML. [26] [27] [28] [29] [30] [31] Since advanced MDS is often treated similarly to AML, with patients offered intensive chemotherapy if they can tolerate it, these patients were combined for this study.
Given the poor overall outcome and high treatment-related mortality in older adults with AML and aMDS, many patients and physicians do not pursue aggressive induction therapy, opting instead for best supportive care with blood product transfusions and/or use of hydroxyurea, low-dose cytarabine, or similar less myelosuppressive therapy. 32 Two randomized controlled trials compared aggressive induction chemotherapy (IC) with an anthracycline-based regimen to nonaggressive therapy in older adults with leukemia. 33, 34 These studies showed a 2.5-4-month survival advantage in the group receiving induction therapy (which was statistically significant only in one 33 ), but the cost in early deaths, length of hospital stay, and transfusional support was substantial. Given the palliative nature of aggressive therapy in 85-95% of older adults with leukemia, this represents an ideal group in whom issues related to the treatment decision-making process and quality of life (QOL) should be explored.
We report the first prospective, longitudinal study examining the decision-making considerations and QOL of older adults with AML and aMDS choosing between IC and nonintensive chemotherapy/best supportive care (NIC). We explored factors influencing the choice of IC vs NIC and described the clinical course and QOL of patients choosing these two different approaches.
Materials and methods

Patients
Patients X60 years of age with a new histologic diagnosis of AML, FAB classification (M0-M7), or MDS, subcategories refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), or chronic myelomonocytic leukemia (CMML) with 5% blasts or greater, were offered participation in this study if they were within 6 weeks of diagnosis upon presentation to a participating institution. No patient had acute promyelocytic leukemia. Patients could have a prior history of other MDS subtypes or another malignancy. Use of hydroxyurea or growth factor support (erythropoietin or granulocyte colony-stimulating factor) prior to study enrollment was acceptable; no patient received prior intensive chemotherapy for MDS or AML. Patients were enrolled upon presentation to the participating institutions at the time they were deciding whether or not to receive intensive IC. Patients then were divided into two cohorts on the basis of their treatment choices: IC or NIC.
Other eligibility criteria included informed verbal and signed consent for study participation; approval from the patient's Dana-Farber or Minneapolis Veterans Administration oncologist; a working knowledge of English (as not all questionnaires have been validated in languages other than English); no psychological contraindications to study participation; and the potential to receive IC, but not allogeneic hematopoietic stem cell transplantation.
Every attempt was made to collect follow-up information at each time point. Missing data are due to death, patient refusal to complete surveys, physician determination that patients were 'medically unfit' (for example, because of intubation or an altered mental status), and inability to contact patients by phone or mail after multiple attempts. If the medical condition allowed, patients could complete subsequent surveys.
All patients were enrolled in either the outpatient or inpatient facilities of the Dana-Farber Cancer Institute (DFCI) or the Minneapolis Veterans Administration Medical Center (MVAMC) between 1 March 2001 and 1 April 2002. This study was approved by the Institutional Review Boards of both institutions, and all patients provided signed informed consent.
Study methods
Study design: Figure 1 shows the timing of patient questionnaires, physician surveys and patient decision interviews collected in this study. In the group of patients receiving IC, the baseline questionnaires were completed either prior to the initiation of therapy, or within 1 day of starting therapy. In the group not receiving intensive chemotherapy, patients completed baseline questionnaires upon presentation to the DFCI or MVAMC. At 2 weeks and at approximately 6 weeks, 10 weeks, 14 weeks, 6 months, and 1 year from the baseline assessment, study participants were contacted again in person or by phone to complete the follow-up questionnaires and for medical data collection. In pilot testing with 10 patients with AML or aMDS, the average time for questionnaire completion was 17.4 min, and the decision interview was completed within 10 min in all cases.
Questionnaires: Shortened versions of questionnaires were used whenever possible to minimize responder burden in this ill population. Questionnaires were either self-administered, or collected as a one-on-one or telephone interview by one of the study investigators (MAS). Baseline and follow-up questionnaires were identical and comprised of well-validated instruments, including the Short Form-12 (SF-12), 35 the Functional Assessment of Cancer Therapy survey, both general and anemiaspecific components (FACT-An), 36, 37 and a shortened version of the Geriatric Depression Scale (GDS). 38 These instruments have been found to be reliable using different modes of administration. 36, 39, 40 Within all measures except the GDS, higher scores indicate a better QOL. The SF-12 is a shortened version of the SF-36, 41 a generic health status instrument measuring QOL and functional status within two domains: physical and emotional. These summary scores are standardized to have a mean score of 50, with a standard deviation of 10, in the general US population. The FACT-An is a modular QOL instrument containing a general section (the FACT-G), with four domains assessing physical well-being, social/family well-being, emotional well-being, and functional well-being, that is sensitive to change in patients receiving chemotherapy. It also contains anemia-specific and fatigue items. The shortened version of the GDS is a screening test for depression in older adults, a selfrating scale intended primarily for clinical applications. It is scored on a 1-15 scale, with a score of 0-4 considered normal; 5-9 indicating mild depression; and 10-15 indicating moderate to severe depression.
In the group of patients receiving IC, the timing of follow-up questionnaire administration was adjusted to correspond to important treatment milestones: The first set was given 2 weeks following the baseline assessment, when blood counts would be expected to be at or approaching their nadirs; the second set was given 1-2 weeks following discharge from the initial hospitalization (the hospitalization when patients received induction chemotherapy), at approximately Week 6 from baseline assessment, to correspond to recovery of blood counts. In patients who received a reinduction course for persistent disease, however, this set of questionnaires was given as many as 75 days from study enrollment. In choosing this study design, we favored clinically meaningful time points rather than a rigid timeline reflecting our primary interest in accurately capturing patients' experiences. NIC patients were given questionnaires at baseline and at approximately two and six weeks from enrollment. In only two cases were Week 6 questionnaires in the NIC group administered more than 1 week from the Week 6 timepoint. Subsequent questionnaires were administered starting approximately four weeks following the Week 6 questionnaire administration date. The Month 6 questionnaires were given approximately 3 months following the Week 14 surveys, and the Year 1 questionnaires approximately 6 months after the Month 6 surveys.
Other data: Patient decision interviews were conducted by phone or in person. Topics included preference for participation in treatment decisions, 42 influences on treatment decisions, and estimates of cure, 1-year survival, and treatment-related mortality. Questions were developed with input from AML patients, hematologic-malignancy nurses, and oncologists specializing in leukemia. Physician surveys were administered within 1 week of patient enrollment, and asked the physician to estimate a patient's chance of cure, 1-year survival, and treatment-related mortality, and included a 'preference for participation in treatment decisions' item. 42 Within the clinical data, 'normalized' blood counts were defined as an absolute neutrophil count (ANC) 41500/mm 3 and Figure 1 Study schema.
a platelet count 4100 000/mm 3 Complications were graded using the National Cancer Institute Common Toxicity Criteria. Any portion of a day spent in the clinic or hospital was considered 1 day.
Statistical analyses
Associations between categorical variables were assessed by a Fisher's exact test. The Wilcoxon rank-sum test was used for testing differences between continuous variables. No statistical adjustment was made for performing multiple tests. All probability values are two-sided.
The weighted k-statistic was used to assess the level of agreement or disagreement between the patient's and doctor's responses. Weights were chosen so that agreement was greater for responses closer to perfect concordance, and the weighted kstatistic and the respective 95% confidence interval were used to summarize the measure of agreement between patient and doctor responses. k equals 0 when the agreement equals that expected by chance and equals 1 when there is perfect agreement. Negative values occur when agreement is weaker than expected by chance.
Treatment differences in QOL scores between baseline and week 2 of the within-patient changes in scores were tested in an ANOVA model. Intrapatient differences, which appeared normally distributed for all QOL scores, were used to analyze changes in QOL from baseline to week 2 and baseline to week 6. In addition, within each treatment group paired t-tests were used to compare within-patient differences between baseline and week 2 and between baseline and week 6.
Results
Patients
A total of 43 patients were enrolled of 44 approached, for a study accrual rate of 98%. Of these, 26 were men and 17 were women. Most (N ¼ 33, 77%) had a diagnosis of AML while 10 (23%) had aMDS. The median age for the overall group was 71 years (Table 1) . 21 patients chose IC (49%), and 22 (51%) opted for NIC. Supplementary Figure 2 (transmitted as supplementary material on the Internet at http://www.nature.com/leu/) shows the number of patients who participated at each assessment point.
Patients choosing IC were younger than those choosing NIC (median age of 66 years, compared to 76 years, P ¼ 0.01) and were more likely to have a diagnosis of AML (95% vs 59%, P ¼ 0.01). As would be expected in the group in which AML is over-represented, IC patients had a higher bone marrow blast percent (60% vs 28%, P ¼ 0.003). Other laboratory results, the number of patients with unfavorable cytogenetics, red blood cell transfusion requirements, ECOG performance status, comorbidities, and the number of patients with secondary AML or aMDS, were similar between groups. Of the 15 patients with secondary disease, 13 patients had a history of antecedent non-Hodgkin's lymphoma or MDS.
QOL instruments: baseline -week 6 QOL scores were similar for IC and NIC groups at baseline (Supplementary Table 2 , transmitted as supplementary material on the Internet at http://www.nature.com/leu/). For the SF-12
Physical component scores were more than one-and-a-half standard deviations below the median score of 50 for the general population. 35 SF-12 mental component scores for those choosing IC and NIC, however, were similar to population norms. For the General FACT and the FACT anemia and fatigue scales, median scores in both groups were similar, and within a half standard deviation of the scores reported when the instrument was validated. 37 The incidence of any depression, as defined by GDS scores, also was similar within both groups (38% for IC patients and 32% for NIC patients) and was 35% for the entire cohort, a prevalence much higher than the 7% found when the GDS was applied in a community-based study of older adults. 43 We analyzed the change in the QOL scores from baseline to week 2 within each treatment arm (Figure 2 ). Between baseline and week 2, there was a significant deterioration in the General FACT and SF-12 Physical Scores for patients receiving IC, all of whom were hospitalized for the 2 weeks following IC (P ¼ 0.04, P ¼ 0.03, respectively). The changes from baseline to week 2 were not significantly different for any of the QOL scores within the cohort of patients not receiving intensive chemotherapy.
By Week 6, when those choosing IC had been discharged from the hospital following remission induction therapy, FACT QOL scores recovered almost completely. For those choosing NIC, scores were not discernibly different from Week 2 and baseline scores, though the SF-12 Physical component score decreased from 35 to 30 and the Mental component score increased from 47 to 54 at Week 6, statistically nonsignificant differences.
The incidence of depression, as determined by the GDS, went from 38% in the IC group at baseline to 26% at 2 weeks and back to 34% at 6 weeks. In the NIC group, on the other hand, the incidence increased from 32% at baseline to 45% at 2 weeks and 47% at 6 weeks. Differences were not significant.
QOL instruments: week 10-year 1
General FACT QOL scores for individual patients over the oneyear duration of the study are displayed in Figure 3 . Overall, scores for patients able to complete surveys appeared to improve in IC patients over the year following remission induction chemotherapy, and remained stable in NIC patients. Similar patterns were evident for FACT anemia and fatigue scales, and for SF-12 scores. High subject attrition rate prevented formal statistical analyses for trends from being performed, though comparisons of median values between groups were not significantly different. The incidence of depression appeared to decrease in those who received IC, falling to 22% at 6 months and 0% at 1 year. In the IC group, it remained in the 25-40% range and reached 50% at 1 year.
Decision interviews
In all, 38 patients went on to complete the Decision Interview, 19 in each group. Five patients were unable to complete the interview due to either death or to being medically unfit (Supplementary Table 3 , transmitted as supplementary material on the Internet at http://www.nature.com/leu/). When patients were asked whether or not they had been offered treatments other than the one they chose, 63% reported that they had not (68% for IC patients and 58% for NIC patients), despite the fact that in all cases, a discussion of alternate options were documented by physicians in office notes. IC patients were more likely than NIC patients to report having their treatment decisions influenced by their physician (74 and 47%, respectively, P ¼ 0.18). Overall, 97% of patients agreed with the statement that QOL was more important to them than length of life, regardless of their choice of therapy.
Patient and physician agreement
Patients and physicians showed great discordance when reporting expectations for outcome (Figure 4 ). Patient estimates for cure and for 1-year survival were similar for both IC and NIC groups, and the two were combined for these analyses. Almost three-fourths of patients (74%) estimated their chance of cure to be X50%, yet physicians estimated the chance of cure to be p10% 89% of the time (k-value for agreement ¼ 0.07 [0, 0.15]). Responses for 1-year survival diverged similarly: 89% of patients gave estimates of X50%, while physician estimates of 1-year survival were p50% 65% of the time (k ¼ 0.07 [0, 0.20]). Physician estimates for cure were lower for patients choosing NIC compared to patients choosing IC (medians of 5% and 10%, P ¼ 0.001), but did not differ for 1-year survival. Patients and physicians showed poor agreement in estimating treatmentrelated mortality, with 50% of patients estimating their chance of dying as a result of therapy as o10%, compared to 5% of physicians (k ¼ 0.14 [0, 0.34]); and in identifying a patient's preference for participation in treatment decisions (k ¼ 0.04 [0, 0.30]): Most patients (68%) identified themselves as sharing equally in decision-making with their physician, making treatment decisions with some input from their physician, or being the sole decision-maker, while most physicians (66%) identified themselves as the sole decision-maker, or as making treatment decisions with some input from patients.
AML patients
Focusing on AML patients alone, 20 chose IC while 13 opted for NIC. QOL scores between the two groups did not differ at Baseline or at Week 6, and did not change appreciably from Baseline to Week 6 within each treatment group. There were no differences between treatment groups in patients reporting whether or not they were offered treatments other than the one they chose or in their outcome estimates. Physician outcome estimates for AML patients choosing IC and NIC paralleled those for the entire population of AML and aMDS patients.
Clinical course
By 6 weeks, the clinical course for the two groups had diverged ( Table 2) . As expected, patients choosing IC received more red blood cell and platelet transfusions than those opting for NIC over the time period of the study. IC patients also spent a majority of their time either in the hospital or in an outpatient clinic, while NIC patients did not (79% of study days for IC patients, with a median (range) of 42 days (25-58), and 14% for NIC patients, with a median (range) of 6 days (3-19), P ¼ 0.0001). Grade 3 or 4 infections occurred in 50% of IC and 21% of NIC patients, while cardiovascular events occurred in 33% and 5.6%, respectively. In total, 10 IC patients and four NIC patients had normalized neutrophil and platelet counts (P ¼ 0.04). Bleeding and renal complications were similar in the two groups, as were ECOG performance status scores and the proportion of patients surviving (86% for each group).
By Year 1, only five patients in each group remained in the study. In the IC group, 12 patients had died, compared to 15 in the NIC group, for a 1-year mortality rate of 63%.
Discussion
Older adults with a new diagnosis of AML or aMDS must decide whether or not to receive IC. This therapy is known to result in a small chance for long-term DFS, but is associated with high upfront morbidity and mortality. Often, this decision is made hurriedly, when patients are feeling ill. The ability to offer guidance based on knowledge of how previous AML or aMDS patients have made similar treatment decisions and the outcomes of those decisions may be helpful. In our study, patients choosing intensive chemotherapy were younger and more likely to have AML than patients opting for NIC or best supportive care. Mortality rates at 6 weeks were similar for the two groups, which could have been predicted based on prior studies comparing IC and NIC in older adults, 33, 34 though appeared to be somewhat higher in the NIC group at 1 year of follow-up. It is possible that with a greater number of patients, more of a difference might have emerged. Baseline QOL scores and prevalence of depression were similar for those choosing IC and those opting for NIC, although both groups were significantly compromised compared to the general population. Therefore, it is not clear that sicker, more depressed patients, or patients with more comorbidities were choosing NIC.
During the first 6 weeks of follow-up QOL scores at Week 2 diminished in the IC group and remained stable in the NIC group compared to baseline results, though by Week 6 these scores had recovered in the IC group. Over the course of 1 year, similar numbers of patients in each treatment group remained on-study, and there is a suggestion that QOL improved in IC patients who completed all seven surveys.
It appears from these results that the effects of treatment on a patient's QOL are limited to the time he or she is in the hospital. Patients may be informed that they can expect their QOL and their ability to function to improve once they leave the hospital, and that it will be similar to their pretreatment scores.
In the decision interview, almost two-thirds of patients denied being offered treatment options other than the one they chose, despite the documentation of these options in the medical record in all cases. There are many possible explanations for this finding. We could not discern whether this communication disconnect occurred because physicians could not explain treatment options clearly, or because patients could not internalize other options due to an 'information overload' close to the time of their diagnosis. Patients were also much more likely to identify themselves as making treatment decisions alone or in concert with a physician, yet they substantially overestimated their chances of cure and one-year survival, regardless of the therapy they chose. Similar disparities occurred in estimating the chance of one-year survival and of treatmentrelated mortality. These overestimates were similar in IC and NIC groups, and probably reflect a core lack of understanding about the natural history of AML and aMDS and the distinction between treatment with intent to cure vs palliation of symptoms.
These discrepancies are concerning because improved patient-physician communication has been shown to be associated with a sense of choice and satisfaction with treatment choice. 44, 45 In addition, outcome estimates are an important part of the initial discussion between a patient and physician regarding the relative benefit of various treatment options, and of the informed consent process. While it is possible that patients gave inflated estimates in a one-on-one interview setting or by telephone, as opposed to a more anonymous selfadministration setting, our results in this older, acutely ill population are consistent with previous studies that examined patients' estimates of the benefits of therapy and the deleterious effects that could occur from therapy. [46] [47] [48] In one survey, 46 318 breast cancer survivors who received adjuvant chemotherapy were asked whether or not they had been told about their prognosis and the value of adjuvant chemotherapy. Only 39% recalled receiving quantitative estimates of their prognosis, and only 31% received an estimate of the benefit of adjuvant chemotherapy. As with the present study, patients grossly overestimated the value of therapy, estimating a risk reduction of recurrence of 79%. Another survey of 313 stem cell transplant recipients found that patients were overly optimistic in estimating treatment-related mortality and DFS when compared to physician estimates and actual 2-year DFS. 47 Patients receiving an autologous transplant estimated their chance of cure to be 70%, while physician estimates were 32% and actual DFS was 44%. This study provides the justification for future studies, which should include observation of the interaction between a patient and physician and input from a family member or surrogate, in an attempt to identify at what level the communication gap occurs. Patients choosing IC had much higher blood product transfusion requirements over the initial 6-week study period than those choosing NIC, had more illnesses, and spent more than five times the number of days in hospital or in the clinic as NIC patients. While we expected this difference based on choice of therapy, we were surprised at the degree of difference, as it is higher than studies performed more than a decade ago. 33, 34 These data could aid in analyzing modern clinical trials in this age cohort that compare chemotherapy to a less intensive treatment approach, using QOL or quality-adjusted life year (QALY) end points.
Our study has a number of limitations. Patients in the IC group differed from those in the NIC group in that they were younger and more likely to have an AML diagnosis. Thus, it is possible there were systematic differences in how information was presented by physicians (for example, IC may have been stressed more for a younger patient with AML than for an older patient with advanced MDS). Future studies that observe patient-physician interactions directly will be able to address these hypotheses. There is no reason for us to believe this occurred, however, as physicians documented different types and intensities of therapeutic options in office notes for all patients, and patients in both groups were equally likely to recognize when other therapies were offered to them. Our findings about decision-making and QOL did not change when AML patients were examined separately.
Our conclusions are limited by the number of patients who were enrolled. Nevertheless, based on clinical outcomes we believe this is a representative patient sample and that our data may be used to counsel and give direct feedback to patients about the QOL impact of the treatment decision they make and to raise awareness among physicians that patients expect much more than what therapy usually offers. Interventions that may help correct misperceptions include: having family members present at meetings with doctors to ask additional questions and record information; explaining treatment options and treatmentrelated mortality and outcome estimates a number of times (either through the use of educational materials, particularly interactive educational materials such as CD-ROMs, or through repeat visits with health care personnel and reiteration of estimates); testing patient understanding of these estimates, to verify that informed consent truly has been given; and early involvement of psychiatry and social services, when appropriate.
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Conclusion
The treatment choice of older patients with AML and aMDS appears to be associated with disease status and age, and not with QOL or perceived differences in the potential risks and benefits of available treatments. Almost two-thirds of patients did not realize that there was more than one treatment option, and they failed to understand their chances of cure, 1-year survival, and treatment-related mortality, regardless of their final treatment choice. Patients with a new diagnosis of AML or aMDS should be counseled about issues that may be important to them, as this will enhance patient satisfaction about the treatment choice that eventually is made. Ideally, patients should be encouraged to participate in decision making with accurate knowledge about the risks and benefits of all available treatment options. This understanding should include not only chances of cure and treatment-related mortality, but also the likely trajectory of QOL with either choice.
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